BLN

FLN (PF3D7_1360800) is an M16-family zinc metallopeptidase of Plasmodium falciparum that functions in intracellular peptide catabolism across two subcellular compartments (PMID:10542284, PMID:17074076). In the acidic food vacuole it acts downstream of the plasmepsins and falcipain in the hemoglobin degradation pathway, cleaving hemoglobin-derived peptide fragments — but not intact hemoglobin or denatured globin — with a distinctive preference for polar/charged residues at P1/P4', contrasting with the hydrophobic preferences of the upstream proteases; the enzyme carries an 'inverted' HXXEH active-site motif characteristic of the M16 family (PMID:10542284). Beyond the food vacuole, FLN localizes to the apicoplast, where it cleaves the transit peptide of the apicoplast acyl carrier protein, implicating it in degradation of transit peptides after protein import (PMID:17074076); consistent with these dual roles, recombinant FLN is active at both acidic and neutral pH and displays markedly different substrate specificities at the two pH regimes (PMID:12876284). Structurally, FLN cycles between an open, substrate-accessible conformation and a closed, catalytically competent state: substrate-bound crystal structures show recognition via antiparallel β-sheet formation with sequence-independent P2/P1 contacts and a preference for tyrosine/phenylalanine at P1', while the antimalarial MK-4815 traps the closed state by binding an allosteric pocket adjacent to a hinge region, blocking the dynamic transition required for the proteolytic cycle (PMID:39217277). Failure to truncate the chromosomal locus and correlation between inhibitor potency against purified enzyme and parasite killing establish FLN as essential for intraerythrocytic parasite survival and a druggable target (PMID:17074076, PMID:29691139).

1. 1999 High

   Establishing where FLN acts in hemoglobin catabolism: it was unknown which protease processed hemoglobin peptide fragments after the primary endoproteases, and purification placed FLN downstream of plasmepsins and falcipain with a complementary charged-residue specificity.

   Evidence Enzyme purification from food vacuoles, peptide cleavage assays, and gene cloning revealing an M16 inverted HXXEH motif

   PMID:10542284

   Open questions at the time

   • Full downstream fate of the resulting peptides not defined
   • No structural basis for the charged-residue preference at this stage
2. 2003 High

   Testing whether FLN is a single-role vacuolar enzyme: pH-dependent activity profiling and imaging showed robust activity and distinct specificity at neutral pH plus association with vesicular structures beyond the food vacuole, raising the possibility of two functional identities.

   Evidence Random peptide substrate profiling of recombinant enzyme plus fluorescence imaging

   PMID:12876284

   Open questions at the time

   • Identity of the second, non-vacuolar compartment not resolved here
   • Physiological neutral-pH substrates not identified
3. 2003 Low

   Characterizing FLN's processing state addressed whether the food vacuole enzyme is proteolytically matured; it was reported as an unprocessed food vacuole enzyme.

   Evidence Biochemical characterization (title-level; abstract unavailable)

   PMID:12798513

   Open questions at the time

   • Abstract not available; details of the processing analysis not confirmable
   • Not independently corroborated within the corpus
4. 2006 High

   Resolving FLN's second location and role: the non-vacuolar signal was assigned to the apicoplast, and FLN was shown to cleave an apicoplast transit peptide, defining a role in transit-peptide degradation and providing the first evidence for essentiality.

   Evidence Chromosomal FLN-GFP fusion live imaging, in vitro transit peptide cleavage assay, and failed gene truncation

   PMID:17074076

   Open questions at the time

   • Failed truncation is indirect evidence of essentiality, not a conditional knockdown
   • How FLN is dually targeted to food vacuole and apicoplast unknown
5. 2018 Medium

   Validating FLN as a drug target: it was unclear whether inhibiting FLN kills parasites, and correlation between hydroxamic acid inhibitor potency against purified enzyme and parasite growth inhibition provided pharmacological support for essentiality and druggability.

   Evidence In vitro enzyme inhibition with purified FLN correlated with cultured parasite growth inhibition and SAR optimization

   PMID:29691139

   Open questions at the time

   • Correlation does not exclude off-target contributions to killing
   • Which of the two compartmental roles is the lethal one not distinguished
6. 2024 High

   Defining the catalytic mechanism and inhibition mode: structures resolved how FLN recognizes substrate and cycles between open and closed states, and showed MK-4815 traps the closed state via an allosteric hinge pocket, explaining inhibition.

   Evidence X-ray crystallography of substrate-bound complexes and cryo-EM of unbound and inhibitor-bound FLN

   PMID:39217277

   Open questions at the time

   • Structures address hemoglobin peptides, not apicoplast transit-peptide recognition
   • Allosteric inhibition validated structurally but not by resistance mapping in parasites

• How FLN is selectively targeted to and functionally partitioned between the food vacuole and apicoplast, and which compartmental function underlies its essentiality, remain unresolved.
• No conditional genetic separation of the two roles
• Trafficking/targeting mechanism to two compartments uncharacterized
• In vivo substrate repertoire in each compartment not fully defined